Expert Perspectives on HSCT: Planning for Success

Slides:



Advertisements
Similar presentations
Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.
Advertisements

Congenital Neutropenia: Making the Decision to Transplant John E. Levine, MD, MS University of Michigan Blood and Marrow Transplantation Program.
The times.. they are a changing Dr. Hamdi Akan Ankara University Medical School Dept. of Hematology.
Hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,
Activity Faculty Scott C. Howard, MD, MSc University of Tennessee College of Health Sciences Memphis, TN.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications FactorUnivariate RR (95% CI)P-valueMultivariate RR *1.
Hematopoietic stem cell transplantation- HSCT. Principle of HSCT Myeloablation and eradication of residual disease with hogh dose conditioning regimen.
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
BENIN BLOOD & MARROW TRANSPLANT SOCIETY OF NIGERIA JULY STEM CELL TRANSPLANT CENTRE, BENIN Graft versus Host Disease in HSCT Anthony Oyekunle.
Due to the non-myeloablative nature of the reduced intensity conditioning, following infusion there is a period of mixed-chimerism with both patient and.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Hematopoietic Stem Cell Current Status and Future Directions
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
Pavan Kumar Bhamidipati 1, John F. DiPersio 1, Keith Stockerl-Goldstein 1, Geoffrey L. Uy 1, Peter Westervelt 1, Feng Gao 2, Ravi Vij 1, Mark A. Schroeder.
New Approaches for Transplant Patients Linda J Burns, MD Medical Director, Health Services Research Program National Marrow Donor Program (NMDP)/Be the.
(Donor T-Cells Transduced with iC9 Suicide Gene)
Stem Cell Transplantation
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies  Marcelo.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation
Supplemental table 1 Patients' characteristics Variables Number
Advances in HSCT: Highlights From the 2013 BMT Tandem Meetings
Allogeneic stem cell transplantation (allo-SCT) is a potentially curative procedure for a variety of malignant and nonmalignant conditions. Historically,
Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Nonmyeloablative conditioning for relapsed follicular lymphoma
Il trapianto allogenico da donatore alternativo dopo condizionamento a ridotta intensità Alessandro Rambaldi.
PREDICTIVE FACTORS AFFECTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION USING RIC REGIMENS: EXPERIENCE FROM A SINGLE CENTRE Dott.ssa M. Medeot.
Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell.
Figure 1 Outline of the AHSCT procedure
Ematologia, Ospedali Riuniti, Bergamo
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
Chapter 51 Management of Patients With Immunodeficiency
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
Figure 2 Components of each transplantation platform
Letermovir(Prevymis™) Guidelines for Inpatient Use
CMV in the HSCT Recipient
Chapter 51 Management of Patients With Immunodeficiency
Ephraim J. Fuchs, Xiao-jun Huang, Jeffrey S. Miller 
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Current Challenges in Managing Hemophilia
Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing.
Biology of Blood and Marrow Transplantation
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.
Joseph Pidala, Stephanie J
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning 
Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.
Persistence of host dendritic cells after transplantation is associated with graft-versus- host disease  Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller,
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation  Merav Bar, Weigang Tong, Megan Othus,
Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom  Haesook T. Kim, Philippe Armand  Biology of Blood.
Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies  Marcelo.
Is KIR- typing relevant to HCT donor selection?
Two Partial T Cell Depletion Strategies for Unrelated Donor Peripheral Stem Cell Transplantation are Associated with Excellent Outcomes for Pediatric.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Clinical Lymphoma, Myeloma and Leukemia
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Selective Immunomodulation in MS
Presentation transcript:

Expert Perspectives on HSCT: Planning for Success

Learning Objectives

Overview

Mobilization of Stem Cells

Bone Marrow vs Peripheral Blood Stem Cells

Mobilizing With GM-CSF and G-CSF

Strategies for Avoiding Mobilization Failure

Conditioning Regimens

Factors to Consider When Selecting a Conditioning Regimen

Comparing Outcomes of Myeloablative vs Nonmyeloablative Conditioning

The Effects of Dose Intensity

Pharmacokinetic Sampling

An Alternative View

CIBMTR Study of Outcomes of Full-Intensity and RIC Regimens

Preventing Relapse

Serotherapy

Preventing GVHD: T-Cell Depletion

Preventing GVHD: T-Cell Depletion (cont)

Newer Pharmacologic Options For Preventing GVHD

Preventing Post-Transplant Infections

A Challenging Case

What Role Should TBI Have?

Conclusions

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.